Alain H. Rook

Dermatology

3400 Civic Center Boulevard
South Pavilion, 1st Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.

Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden.

Journal: Blood neoplasia

Published: February 09, 2026

Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 09, 2026

Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis.

Standard Versus Hypofractionated Low-Dose Total Skin Electron Therapy for Cutaneous T-Cell Lymphoma: A Single-Institution Retrospective Analysis.

Journal: Practical radiation oncology

Published: December 16, 2025

High-Throughput Sequencing and Estimated Relapse Risk in Patients With Sézary Syndrome.

High-Throughput Sequencing and Estimated Relapse Risk in Patients With Sézary Syndrome.

Journal: JAMA dermatology

Published: September 03, 2025

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Journal: Blood

Published: September 02, 2025

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

Journal: Blood

Published: September 02, 2025

Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells.

Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells.

Journal: Cancer immunology research

Published: August 11, 2025

Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.

Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment.

Journal: Cancers

Published: May 19, 2025

Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.

Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.

Journal: JAMA dermatology

Published: April 02, 2025

Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study.

Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study.

Journal: Veterinary oncology (London, England)

Published: January 14, 2025

Cutaneous T-cell Lymphoma.

Cutaneous T-cell Lymphoma.

Journal: Hematology/oncology clinics of North America

Published: July 30, 2024

Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.

Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome.

Journal: Journal of the American Academy of Dermatology

Published: July 21, 2024

Showing 1-12 of 83

Last Updated: 09/26/2026